John M L Ebos
Overview
Explore the profile of John M L Ebos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi Y, McKenery A, Dolan M, Mastri M, Hill J, Dommer A, et al.
EMBO Rep
. 2024 Dec;
26(2):521-559.
PMID: 39663510
Therapeutic inhibition of programmed cell death ligand (PD-L1) is linked to alterations in interferon (IFN) signaling. Since IFN-regulated intracellular signaling can control extracellular secretory programs in tumors to modulate immunity,...
2.
Dolan M, Shi Y, Mastri M, Long M, McKenery A, Hill J, et al.
Mol Cancer Ther
. 2024 Jun;
:OF1-OF20.
PMID: 38896060
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly....
3.
Benzekry S, Mastri M, Nicolo C, Ebos J
PLoS Comput Biol
. 2024 May;
20(5):e1012088.
PMID: 38701089
Clinical trials involving systemic neoadjuvant treatments in breast cancer aim to shrink tumors before surgery while simultaneously allowing for controlled evaluation of biomarkers, toxicity, and suppression of distant (occult) metastatic...
4.
Boland P, Ebos J, Attwood K, Mastri M, Fountzilas C, Iyer R, et al.
JNCI Cancer Spectr
. 2024 May;
8(3).
PMID: 38697618
Background: Nintedanib is a tyrosine kinase inhibitor with efficacy in bevacizumab-resistant colorectal cancer models. This phase I/II study evaluated the recommended phase II dose and efficacy of nintedanib and capecitabine...
5.
Dolan M, Shi Y, Mastri M, Long M, McKenery A, Hill J, et al.
Mol Cancer Ther
. 2024 May;
PMID: 38690835
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) disrupt tumor angiogenesis but also have many unexpected side-effects that impact tumor cells directly. This includes the...
6.
Tzetzo S, Kramer E, Mohammadpour H, Kim M, Rosario S, Yu H, et al.
iScience
. 2024 Feb;
27(3):109187.
PMID: 38420590
Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic sites, yet their functional contributions to metastasis remain incompletely understood. Here, we show that alveolar macrophages (AMs), the main TRMs of...
7.
Torres-Estay V, Mastri M, Rosario S, Fuenzalida P, Echeverria C, Flores E, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230673
The survival of patients with solid tumors, such as prostate cancer (PCa), has been limited and fleeting with anti-angiogenic therapies. It was previously thought that the mechanism by which the...
8.
He X, Zhou S, Dolan M, Shi Y, Wang J, Quinn B, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34862254
Background: Induction of CD8 T cells that recognize immunogenic, mutated protein fragments in the context of major histocompatibility class I (MHC-I) is a pressing challenge for cancer vaccine development. Methods:...
9.
Oshi M, Katsuta E, Yan L, Ebos J, Rashid O, Matsuyama R, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32370309
We generated a 4-gene score with genes upregulated in LM2-4, a metastatic variant of MDA-MB-231 (DOK 4, HCCS, PGF, and SHCBP1) that was strongly associated with disease-free survival (DFS) in...
10.
Vaghi C, Rodallec A, Fanciullino R, Ciccolini J, Mochel J, Mastri M, et al.
PLoS Comput Biol
. 2020 Feb;
16(2):e1007178.
PMID: 32097421
Tumor growth curves are classically modeled by means of ordinary differential equations. In analyzing the Gompertz model several studies have reported a striking correlation between the two parameters of the...